Digestive and Liver Disease
Volume 42, Issue 5 , Pages 359-364, May 2010

Gastro-protective strategies in primary care in Italy: The “Gas.Pro.” survey

  • Maria A. Bianco

      Affiliations

    • U.O.C. di Gastroenterologia – Ospedale Maresca, Torre del Greco, Viale degli Aranci 2, 80131 Naples, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 081 8490109; fax: +39 081 8490109.
  • ,
  • Gianluca Rotondano

      Affiliations

    • U.O.C. di Gastroenterologia – Ospedale Maresca, Torre del Greco, Viale degli Aranci 2, 80131 Naples, Italy
  • ,
  • Luigi Buri

      Affiliations

    • SC Gastroenterologia – Ospedale di Cattinara, Trieste, Italy
  • ,
  • Francesco Tessari

      Affiliations

    • CED-IDEA 99 srl-Padova, Italy
  • ,
  • Livio Cipolletta

      Affiliations

    • U.O.C. di Gastroenterologia – Ospedale Maresca, Torre del Greco, Viale degli Aranci 2, 80131 Naples, Italy
  • ,
  • for the Gas.Pro. Italian Group

Received 29 May 2009; accepted 15 November 2009. published online 11 December 2009.

Abstract 

Introduction

Risk of gastrointestinal injury is relevant among users of anti-inflammatory or cardio-protective drugs. Adequate gastro-protection is warranted in high-risk patients.

Aim

To assess the perceptions and practices of Italian primary care physicians regarding gastro-protective strategies.

Methods

Nationwide cross-sectional observational study. A 14-question survey questionnaire was administered to 112 primary care physicians throughout Italy. Data collection covered consecutive outpatient candidates for the prescription of a potentially GI harmful medication, observed in the physicians’ office over a 3-week period.

Results

Cohort included 3943 cases (2489 naïve and 1463 chronic NSAID/ASA users). Mean age and prevalence of cardiovascular comorbidity were significantly higher in the latter subgroup. Non-selective NSAIDs and low-dose aspirin were the most commonly prescribed drugs. Combined NSAIDS/ASA plus steroids/anticoagulant/antiplatelets were recorded in 161 cases. Helicobacter pylori status was known in only 38% of naïve and 33.2% of chronic users, being negative in 85.3% and 89.5%, respectively. When positive, H. pylori was eradicated by almost all physicians (97.9%), but in case of unknown H. pylori status, the presence of infection was investigated in only 8.6% and 14.9% of patients in the two subgroups. Gastro-protection was endorsed in 80.7% of patients, mostly PPIs (91%). In patients aged over 70, pantoprazole and lansoprazole were the preferred gastro-protective agents.

Conclusions

There is a significant over-use of gastro-protection in the primary care setting in Italy and the role H. pylori is largely overlooked. Educational efforts should be directed to a more targeted gastro-protection only for at-risk patients as well as improved adherence to recommendations for testing and treating H. pylori infection.

Keywords: Gastro-protection, Drug-related GI injury, Preventive strategies, Primary care

Abbreviations: PCP, primary care physician, GPA, gastro-protective agents, NSAIDs, non-steroidal anti-inflammatory drugs, ASA, acetyl salycilic acid, PPI, proton pump inhibitor, EDP, electronic data processing

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1590-8658(09)00438-1

doi:10.1016/j.dld.2009.11.003

Digestive and Liver Disease
Volume 42, Issue 5 , Pages 359-364, May 2010